The Department of Pharmaceuticals is implementing the Production Linked Incentive (PLI) Scheme for Pharmaceuticals with a total financial outlay of Rs 15,000 crore and scheme tenure up to FY 2027-28. The scheme provides financial incentives to 55 selected applicants for manufacturing identified products under three categories for a period of six years. The product Category 1 covers drugs such as bio-pharmaceuticals, complex generics, gene therapy drugs, complex excipients, orphan drugs etc. Orphan drugs are those drugs which are used for the treatment of rare diseases. Under the scheme, a total of 8 orphan drugs have been approved for manufacturing. The orphan drugs approved under the PLI scheme for Pharmaceuticals are as follows:
| Sr. No. | Name of the product | Usage |
| 1 | Nitisinone | Treatment of Hereditary Tyrosinemia Type 1 |
| 2 | Nusinersen | Treatment of Spinal Muscular Atrophy |
| 3 | Rufinamide | Treatment of Lennox-Gastaut syndrome. |
| 4 | Sodium Phenyl Butyrate | Treatment of Urea Cycle Disorders |
| 5 | Tiopronin | Prevention of Cystine Nephrolithiasis |
| 6 | Trientine Hydrochloride | Treatment of Wilson’s disease |
| 7 | Eliglustat | Treatment of Gaucher’s disease |
| 8 | Cannabidiol | Treatment of Dravet-Lennox Gastaut syndrome |
This information was given by the Union Minister of State for Chemicals and Fertilizers Anupriya Patel in Lok Sabha.
The post appeared first on .